Related references
Note: Only part of the references are listed.Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells
Hyangsoon Noh et al.
CELL COMMUNICATION AND SIGNALING (2015)
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Daniel Sanghoon Shin et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence
Christina Wefers et al.
GYNECOLOGIC ONCOLOGY (2015)
Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes-Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immune checkpoint modulation: Rational design of combination strategies
Dmitriy Zamarin et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Checkpoint inhibitors in immunotherapy of ovarian cancer
Dong-hui Wang et al.
TUMOR BIOLOGY (2015)
Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
Lei Lu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
Jason R. Westin et al.
LANCET ONCOLOGY (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
Zhiqiang Guo et al.
PLOS ONE (2014)
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Giovanni Germano et al.
CANCER CELL (2013)
Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
Jaikumar Duraiswamy et al.
CANCER RESEARCH (2013)
Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells
Ignacio Melero et al.
CLINICAL CANCER RESEARCH (2013)
Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer
Zhiqiang Guo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Combinatorial PD-1 Blockade and CD137 Activation Has Therapeutic Efficacy in Murine Cancer Models and Synergizes with Cisplatin
Huafeng Wei et al.
PLOS ONE (2013)
CD4 CTL: Living up to the challenge
Hilde Cheroutre et al.
SEMINARS IN IMMUNOLOGY (2013)
Cancer treatment and survivorship statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Antigen-specific Immunotherapy in Ovarian Cancer and p53 as Tumor Antigen
Renee Vermeij et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis
Bradley J. Monk et al.
EUROPEAN JOURNAL OF CANCER (2012)
Silencing of the TGF-β1 Gene Increases the Immunogenicity of Cells From Human Ovarian Carcinoma
Huafeng Wei et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Immunotherapy in ovarian cancer
Gina M. Mantia-Smaldone et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
Immunotherapy for Ovarian Cancer: What's Next?
Lana E. Kandalaft et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Review of Trabectedin (ET-743): A Unique Mechanism of Action
Maurizio D'Incalci et al.
MOLECULAR CANCER THERAPEUTICS (2010)
The biology of ovarian cancer: new opportunities for translation
Robert C. Bast et al.
NATURE REVIEWS CANCER (2009)
Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: A pilot study of safety, feasibility, and immune activation
Dan Laheru et al.
CLINICAL CANCER RESEARCH (2008)
Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis
Ping Zhang et al.
MOLECULAR IMMUNOLOGY (2008)
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
F. Stephen Hodi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
RF Ozols et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells
V Ramakrishna et al.
INTERNATIONAL IMMUNOLOGY (2003)
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
FS Hodi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer
AD Santin et al.
GYNECOLOGIC AND OBSTETRIC INVESTIGATION (2001)
Share Paper
